Faithful preclinical mouse models for better translation to bedside in the field of immuno-oncology

The success of immunotherapy using immune checkpoint inhibitors has changed the practice of cancer treatment tremendously. However, there are still many clinical challenges, such as drug resistance, predictive biomarker development, exploration of combination therapies, and prediction of immune-rela...

Full description

Saved in:
Bibliographic Details
Published in:International journal of clinical oncology 2020-05, Vol.25 (5), p.831-841
Main Authors: Saito, Ryoichi, Kobayashi, Takashi, Kashima, Soki, Matsumoto, Keiyu, Ogawa, Osamu
Format: Article
Language:English
Subjects:
Animal models
Cancer immunotherapy
Cancer Research
Cell culture
Drug resistance
Immune checkpoint inhibitors
Immunotherapy
Invited Review Article
Medicine
Medicine & Public Health
Oncology
Surgical Oncology
Translation
Tumor cell lines
Xenografts
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c465t-1cdc56b91f56a81e617f785ef732e81a1646a57cf1230b6864c829d7f6949b793
cites cdi_FETCH-LOGICAL-c465t-1cdc56b91f56a81e617f785ef732e81a1646a57cf1230b6864c829d7f6949b793
container_end_page 841
container_issue 5
container_start_page 831
container_title International journal of clinical oncology
container_volume 25
creator Saito, Ryoichi
Kobayashi, Takashi
Kashima, Soki
Matsumoto, Keiyu
Ogawa, Osamu
description The success of immunotherapy using immune checkpoint inhibitors has changed the practice of cancer treatment tremendously. However, there are still many clinical challenges, such as drug resistance, predictive biomarker development, exploration of combination therapies, and prediction of immune-related adverse events in preclinical settings. To overcome these problems, it is essential to establish faithful preclinical mouse models that recapitulate the clinical features, molecular genetics, biological heterogeneity, and immune microenvironment of human cancers. Here we review the advantages and disadvantages of current preclinical mouse models, including syngeneic murine tumor cell lines, autochthonous tumor models, cancer cell line-derived xenografts, patient-derived-xenografts, and various kinds of immunologically humanized mice. We discuss how these models should be characterized and applied in preclinical settings, and how we should prepare preclinical studies for successful translation from bench to bedside.
doi_str_mv 10.1007/s10147-019-01520-z
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2272734142</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2272734142</sourcerecordid><originalsourceid>FETCH-LOGICAL-c465t-1cdc56b91f56a81e617f785ef732e81a1646a57cf1230b6864c829d7f6949b793</originalsourceid><addsrcrecordid>eNp9kUFPHiEQhompqdb2D_TQkPTSy1aGZZndY2Nqa2LixZ4Jyw6KYZevsHvQXy_6aZv00AMDA8-8wLyMfQTxFYTA0wICFDYChjo6KZqHA3YMqsUGEeWbum4VNIOW3RF7V8qdEIC6k2_ZUQtKIOj-mLlzG9Zbv0W-y-RiWIKzkc9pK1TjRLFwnzIfaV0p8zXbpUS7hrTwNdXdqYSJeKjZLXEfKE48eR7meVtSkxaXYrq5f88OvY2FPrzMJ-zX-ffrs5_N5dWPi7Nvl41TulsbcJPr9DiA77TtgTSgx74jj62kHixopW2HzoNsxah7rVwvhwm9HtQw4tCesC973V1Ovzcqq5lDcRSjXah-yEiJEmtLlKzo53_Qu7Tlpb7umRKqB3yi5J5yOZWSyZtdDrPN9waEebLA7C0w1QLzbIF5qEWfXqS3cabpT8lrzyvQ7oFSj5Ybyn_v_o_sIwYckaM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2272048172</pqid></control><display><type>article</type><title>Faithful preclinical mouse models for better translation to bedside in the field of immuno-oncology</title><source>Springer Nature</source><creator>Saito, Ryoichi ; Kobayashi, Takashi ; Kashima, Soki ; Matsumoto, Keiyu ; Ogawa, Osamu</creator><creatorcontrib>Saito, Ryoichi ; Kobayashi, Takashi ; Kashima, Soki ; Matsumoto, Keiyu ; Ogawa, Osamu</creatorcontrib><description>The success of immunotherapy using immune checkpoint inhibitors has changed the practice of cancer treatment tremendously. However, there are still many clinical challenges, such as drug resistance, predictive biomarker development, exploration of combination therapies, and prediction of immune-related adverse events in preclinical settings. To overcome these problems, it is essential to establish faithful preclinical mouse models that recapitulate the clinical features, molecular genetics, biological heterogeneity, and immune microenvironment of human cancers. Here we review the advantages and disadvantages of current preclinical mouse models, including syngeneic murine tumor cell lines, autochthonous tumor models, cancer cell line-derived xenografts, patient-derived-xenografts, and various kinds of immunologically humanized mice. We discuss how these models should be characterized and applied in preclinical settings, and how we should prepare preclinical studies for successful translation from bench to bedside.</description><identifier>ISSN: 1341-9625</identifier><identifier>EISSN: 1437-7772</identifier><identifier>DOI: 10.1007/s10147-019-01520-z</identifier><identifier>PMID: 31407168</identifier><language>eng</language><publisher>Singapore: Springer Singapore</publisher><subject>Animal models ; Cancer immunotherapy ; Cancer Research ; Cell culture ; Drug resistance ; Immune checkpoint inhibitors ; Immunotherapy ; Invited Review Article ; Medicine ; Medicine &amp; Public Health ; Oncology ; Surgical Oncology ; Translation ; Tumor cell lines ; Xenografts</subject><ispartof>International journal of clinical oncology, 2020-05, Vol.25 (5), p.831-841</ispartof><rights>Japan Society of Clinical Oncology 2019</rights><rights>Japan Society of Clinical Oncology 2019.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c465t-1cdc56b91f56a81e617f785ef732e81a1646a57cf1230b6864c829d7f6949b793</citedby><cites>FETCH-LOGICAL-c465t-1cdc56b91f56a81e617f785ef732e81a1646a57cf1230b6864c829d7f6949b793</cites><orcidid>0000-0002-3163-8723</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31407168$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Saito, Ryoichi</creatorcontrib><creatorcontrib>Kobayashi, Takashi</creatorcontrib><creatorcontrib>Kashima, Soki</creatorcontrib><creatorcontrib>Matsumoto, Keiyu</creatorcontrib><creatorcontrib>Ogawa, Osamu</creatorcontrib><title>Faithful preclinical mouse models for better translation to bedside in the field of immuno-oncology</title><title>International journal of clinical oncology</title><addtitle>Int J Clin Oncol</addtitle><addtitle>Int J Clin Oncol</addtitle><description>The success of immunotherapy using immune checkpoint inhibitors has changed the practice of cancer treatment tremendously. However, there are still many clinical challenges, such as drug resistance, predictive biomarker development, exploration of combination therapies, and prediction of immune-related adverse events in preclinical settings. To overcome these problems, it is essential to establish faithful preclinical mouse models that recapitulate the clinical features, molecular genetics, biological heterogeneity, and immune microenvironment of human cancers. Here we review the advantages and disadvantages of current preclinical mouse models, including syngeneic murine tumor cell lines, autochthonous tumor models, cancer cell line-derived xenografts, patient-derived-xenografts, and various kinds of immunologically humanized mice. We discuss how these models should be characterized and applied in preclinical settings, and how we should prepare preclinical studies for successful translation from bench to bedside.</description><subject>Animal models</subject><subject>Cancer immunotherapy</subject><subject>Cancer Research</subject><subject>Cell culture</subject><subject>Drug resistance</subject><subject>Immune checkpoint inhibitors</subject><subject>Immunotherapy</subject><subject>Invited Review Article</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Oncology</subject><subject>Surgical Oncology</subject><subject>Translation</subject><subject>Tumor cell lines</subject><subject>Xenografts</subject><issn>1341-9625</issn><issn>1437-7772</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNp9kUFPHiEQhompqdb2D_TQkPTSy1aGZZndY2Nqa2LixZ4Jyw6KYZevsHvQXy_6aZv00AMDA8-8wLyMfQTxFYTA0wICFDYChjo6KZqHA3YMqsUGEeWbum4VNIOW3RF7V8qdEIC6k2_ZUQtKIOj-mLlzG9Zbv0W-y-RiWIKzkc9pK1TjRLFwnzIfaV0p8zXbpUS7hrTwNdXdqYSJeKjZLXEfKE48eR7meVtSkxaXYrq5f88OvY2FPrzMJ-zX-ffrs5_N5dWPi7Nvl41TulsbcJPr9DiA77TtgTSgx74jj62kHixopW2HzoNsxah7rVwvhwm9HtQw4tCesC973V1Ovzcqq5lDcRSjXah-yEiJEmtLlKzo53_Qu7Tlpb7umRKqB3yi5J5yOZWSyZtdDrPN9waEebLA7C0w1QLzbIF5qEWfXqS3cabpT8lrzyvQ7oFSj5Ybyn_v_o_sIwYckaM</recordid><startdate>20200501</startdate><enddate>20200501</enddate><creator>Saito, Ryoichi</creator><creator>Kobayashi, Takashi</creator><creator>Kashima, Soki</creator><creator>Matsumoto, Keiyu</creator><creator>Ogawa, Osamu</creator><general>Springer Singapore</general><general>Springer Nature B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-3163-8723</orcidid></search><sort><creationdate>20200501</creationdate><title>Faithful preclinical mouse models for better translation to bedside in the field of immuno-oncology</title><author>Saito, Ryoichi ; Kobayashi, Takashi ; Kashima, Soki ; Matsumoto, Keiyu ; Ogawa, Osamu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c465t-1cdc56b91f56a81e617f785ef732e81a1646a57cf1230b6864c829d7f6949b793</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Animal models</topic><topic>Cancer immunotherapy</topic><topic>Cancer Research</topic><topic>Cell culture</topic><topic>Drug resistance</topic><topic>Immune checkpoint inhibitors</topic><topic>Immunotherapy</topic><topic>Invited Review Article</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Oncology</topic><topic>Surgical Oncology</topic><topic>Translation</topic><topic>Tumor cell lines</topic><topic>Xenografts</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Saito, Ryoichi</creatorcontrib><creatorcontrib>Kobayashi, Takashi</creatorcontrib><creatorcontrib>Kashima, Soki</creatorcontrib><creatorcontrib>Matsumoto, Keiyu</creatorcontrib><creatorcontrib>Ogawa, Osamu</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Saito, Ryoichi</au><au>Kobayashi, Takashi</au><au>Kashima, Soki</au><au>Matsumoto, Keiyu</au><au>Ogawa, Osamu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Faithful preclinical mouse models for better translation to bedside in the field of immuno-oncology</atitle><jtitle>International journal of clinical oncology</jtitle><stitle>Int J Clin Oncol</stitle><addtitle>Int J Clin Oncol</addtitle><date>2020-05-01</date><risdate>2020</risdate><volume>25</volume><issue>5</issue><spage>831</spage><epage>841</epage><pages>831-841</pages><issn>1341-9625</issn><eissn>1437-7772</eissn><abstract>The success of immunotherapy using immune checkpoint inhibitors has changed the practice of cancer treatment tremendously. However, there are still many clinical challenges, such as drug resistance, predictive biomarker development, exploration of combination therapies, and prediction of immune-related adverse events in preclinical settings. To overcome these problems, it is essential to establish faithful preclinical mouse models that recapitulate the clinical features, molecular genetics, biological heterogeneity, and immune microenvironment of human cancers. Here we review the advantages and disadvantages of current preclinical mouse models, including syngeneic murine tumor cell lines, autochthonous tumor models, cancer cell line-derived xenografts, patient-derived-xenografts, and various kinds of immunologically humanized mice. We discuss how these models should be characterized and applied in preclinical settings, and how we should prepare preclinical studies for successful translation from bench to bedside.</abstract><cop>Singapore</cop><pub>Springer Singapore</pub><pmid>31407168</pmid><doi>10.1007/s10147-019-01520-z</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0002-3163-8723</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 1341-9625
ispartof International journal of clinical oncology, 2020-05, Vol.25 (5), p.831-841
issn 1341-9625
1437-7772
language eng
recordid cdi_proquest_miscellaneous_2272734142
source Springer Nature
subjects Animal models
Cancer immunotherapy
Cancer Research
Cell culture
Drug resistance
Immune checkpoint inhibitors
Immunotherapy
Invited Review Article
Medicine
Medicine & Public Health
Oncology
Surgical Oncology
Translation
Tumor cell lines
Xenografts
title Faithful preclinical mouse models for better translation to bedside in the field of immuno-oncology
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T23%3A13%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Faithful%20preclinical%20mouse%20models%20for%20better%20translation%20to%20bedside%20in%20the%20field%20of%20immuno-oncology&rft.jtitle=International%20journal%20of%20clinical%20oncology&rft.au=Saito,%20Ryoichi&rft.date=2020-05-01&rft.volume=25&rft.issue=5&rft.spage=831&rft.epage=841&rft.pages=831-841&rft.issn=1341-9625&rft.eissn=1437-7772&rft_id=info:doi/10.1007/s10147-019-01520-z&rft_dat=%3Cproquest_cross%3E2272734142%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c465t-1cdc56b91f56a81e617f785ef732e81a1646a57cf1230b6864c829d7f6949b793%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2272048172&rft_id=info:pmid/31407168&rfr_iscdi=true